Purpose Durable and long-term responses to the poly (ADP-ribose) polymerase inhibitor
olaparib are observed in patients without BRCA1/2 mutations. However, beyond BRCA1/2 …

Purpose: Maintenance therapy with olaparib has improved progression-free survival in
women with high-grade serous ovarian cancer (HGSOC), particularly those harboring …

Purpose Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy
using poly (ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers …

Purpose Olaparib (AZD2281), an orally active poly (ADP-ribose) polymerase inhibitor that
induces synthetic lethality in BRCA1-or BRCA2-deficient cells, has shown promising clinical …

Background Olaparib (AZD2281) is an oral poly (adenosine diphosphate [ADP]–ribose)
polymerase inhibitor that has shown antitumor activity in patients with high-grade serous …

To gain a better understanding of the role of somatic mutations in olaparib response, next-
generation sequencing (NGS) of BRCA1 and BRCA2 was performed as part of a planned …

Background Olaparib is a novel, orally active poly (ADP-ribose) polymerase (PARP) inhibitor
that induces synthetic lethality in homozygous BRCA-deficient cells. We aimed to assess the …

Purpose Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline
BRCA1 and BRCA2 (BRCA1/2)–associated breast and ovarian cancers. We evaluated the …

5500 Background: Olaparib (AZD2281; KU-0059436) is a novel, orally active PARP inhibitor
that induces synthetic lethality in homozygous BRCA-deficient cells. A phase I trial identified …

5505 Background: Previously, we reported that maintenance treatment with the oral PARP
inhibitor olaparib (400 mg bid) led to a significant PFS improvement vs placebo in patients …